The accomplished cardiologist has been on Cleveland Clinic’s staff since 2003, directing the cath lab and section of interventional cardiology and building a global reputation as a top clinical researcher.
A new analysis of the large TVT Registry provides the strongest evidence to date of a prognostic benefit from renin-angiotensin system inhibitor therapy following transcatheter aortic valve replacement.
Can standardized metrics of efficiency in the cath lab improve the value of cath lab care? A new review paper makes the case with examples and a proposed set of nine metrics.
The most comprehensive literature review of structural valve deterioration to date just took on this question. Although data were abundant, useful comparisons were few. The authors explain.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Experts advise on developments to look for in the transcatheter space when it comes to managing diseases of the mitral, tricuspid and pulmonary valves.
The next waves of progress in transcatheter aortic valve replacement are likely to involve expanding indications, valve refinements and new accessory treatments.
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.
Our experts outline their vision of ideal changes to the National Coverage Determination for programs performing transcatheter aortic valve replacement. A CMS decision is due in June 2019.
The investigational GATE tricuspid valved stent is the first transcatheter prosthesis to be placed directly at the tricuspid annulus in humans. Our specialists who performed the first case discuss the technology’s evolution.
Findings from three Cleveland Clinic real-world studies suggest a wider range of patients stand to benefit from the left atrial appendage closure device.